Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 4/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.39 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 6/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13128552 | 0.85 | CNR2 (0.39) | BDKRB1CYP2C19RAB9A | |
| SCHEMBL2807962 | 0.85 | F11 (0.35) | HDAC3HDAC1HDAC2HDAC6BDKRB1 | |
| SCHEMBL2811921 | 0.80 | HDAC3 (0.38) | HDAC3HDAC1HDAC2HDAC6BDKRB1 | |
| SCHEMBL2807389 | 0.79 | BDKRB1 (0.42) | BDKRB1CYP3A4CYP2C9CYP2C19NPC1 | |
| SCHEMBL2805326 | 0.78 | CNR2 (0.37) | HDAC3HDAC1HDAC2HDAC6BDKRB1 | |
| SCHEMBL13129191 | 0.78 | CNR2 (0.39) | CYP3A4CYP2C9CYP2C19RAB9A | |
| SCHEMBL2808636 | 0.77 | BDKRB1 (0.41) | HDAC3HDAC1HDAC2HDAC6BDKRB1 | |
| SCHEMBL13128603 | 0.77 | BDKRB1 (0.43) | BDKRB1CYP3A4CYP2C9CYP2C19RAB9A | |
| SCHEMBL2810010 | 0.77 | RAB9A (0.39) | BDKRB1CYP2C19RAB9A | |
| SCHEMBL186523 | 0.77 | RAB9A (0.39) | BDKRB1GRM5CYP2C19RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | HDAC3 1696/4885HDAC1 1428/4885HDAC2 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.